Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, International Joint Laboratory of Ocular Diseases, School of Pharmacy, School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin 300070, China.
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
ACS Nano. 2024 Jul 2;18(26):17267-17281. doi: 10.1021/acsnano.4c04901. Epub 2024 Jun 13.
Intrinsic or acquired resistance to chemical drugs severely limits their therapeutic efficacy in cancer treatment. Various intracellular antioxidant molecules, particularly glutathione (GSH), play a crucial role in maintaining intracellular redox homeostasis by mitigating the overproduced reactive oxygen species (ROS) due to rapid cell proliferation. Notably, these antioxidants also eliminate chemical-drug-induced ROS, eventually diminishing their cytotoxicity and rendering them less effective. In this study, we combined erastin, a GSH biosynthesis inhibitor, with 2'-deoxy-5-fluorouridine 5'-monophosphate sodium salt (FdUMP), an ROS-based drug, to effectively disrupt intracellular redox homeostasis and reverse chemotherapy resistance. Therefore, efficient ferroptosis and apoptosis were simultaneously induced for enhanced antitumor effects. Additionally, we employed small interfering RNA targeting PD-L1 (siPD-L1) as a third agent to block immune-checkpoint recognition by CD8 T cells. The highly immunogenic cell peroxidates or damage-associated molecular patterns (DAMPs) induced by erastin acted synergistically with downregulated PD-L1 to enhance the antitumor effects. To codeliver these three drugs simultaneously and efficiently, we designed GE11 peptide-modified lipid nanoparticles (LNPs) containing calcium phosphate cores to achieve high encapsulation efficiencies. studies verified its enhanced cytotoxicity, efficient intracellular ROS induction and GSH/GPX4 downregulation, substantial lipid peroxidation product accumulation, and mitochondrial depolarization. , this formulation effectively accumulated at tumor sites and achieved significant tumor inhibition in subcutaneous colon cancer (CRC) mouse models with a maximum tumor inhibition rate of 83.89% at a relatively low dose. Overall, a strategy to overcome clinical drug resistance was verified in this study by depleting GSH and activating adaptive immunity.
内在或获得性化学药物耐药性严重限制了其在癌症治疗中的疗效。各种细胞内抗氧化分子,特别是谷胱甘肽 (GSH),通过减轻由于快速细胞增殖而产生的过多活性氧物种 (ROS),在维持细胞内氧化还原稳态方面发挥着至关重要的作用。值得注意的是,这些抗氧化剂还消除了化学药物诱导的 ROS,最终降低了它们的细胞毒性,使其效果降低。在这项研究中,我们将 GSH 生物合成抑制剂 erastin 与 2'-脱氧-5-氟尿苷 5'-单磷酸钠盐 (FdUMP) 结合使用,FdUMP 是一种基于 ROS 的药物,有效破坏细胞内氧化还原稳态并逆转化疗耐药性。因此,同时有效地诱导铁死亡和细胞凋亡,以增强抗肿瘤效果。此外,我们还使用了针对 PD-L1 的小干扰 RNA (siPD-L1) 作为第三种药物,阻断 CD8 T 细胞的免疫检查点识别。erastin 诱导的高度免疫原性细胞过氧化物或损伤相关分子模式 (DAMPs) 与下调的 PD-L1 协同作用,增强了抗肿瘤效果。为了同时高效地共递送这三种药物,我们设计了含有磷酸钙核的 GE11 肽修饰脂质纳米粒 (LNP) 以实现高包封效率。 研究证实了其增强的细胞毒性、高效的细胞内 ROS 诱导和 GSH/GPX4 下调、大量脂质过氧化产物积累和线粒体去极化。, 该制剂能够有效地在肿瘤部位积累,并在皮下结肠癌 (CRC) 小鼠模型中实现显著的肿瘤抑制,在较低剂量下最大肿瘤抑制率达到 83.89%。总体而言,本研究通过耗竭 GSH 和激活适应性免疫验证了克服临床耐药性的策略。